Paper Details

  1. Home
  2. Paper Details

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Author: AndrulisMindaugas, BennerAxel, BertschUta, BlauIgor W, DuerigJan, FenkRoland, FronhoffsStefan, GoldschmidtHartmut, GraevenUllrich, HaenelMathias, HansenTimon, HenselManfred, HillengassJens, HoseDirk, HuhnStefanie, HundemerMichael, JauchAnna, KunzChristina, LindemannHans-Walter, MartensUwe, MunderMarkus, RaabMarc Steffen, SalwenderHans, ScheidChristof, Seidel-GlaetzerAndrea, WattadMohammed, WeiselKatja

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This phase III trial (GMMG-HD6) investigates the role of elotuzumab in combination with bortezomib, lenalidomide, and dexamethasone (VRD) as induction/consolidation and lenalidomide maintenance treatment for younger patients with multiple myeloma.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537200/

データ提供：米国国立医学図書館（NLM）

Elotuzumab: A New Hope for Myeloma Treatment

Multiple myeloma, a cancer of plasma cells, is a challenging disease to treat. This study investigates the potential of elotuzumab, a new drug that targets SLAMF7, a protein found on myeloma cells, in combination with other standard therapies for multiple myeloma. The researchers aim to assess the effectiveness of elotuzumab in achieving deeper remissions and improving overall survival in patients with newly diagnosed myeloma.

A New Caravan for Treatment: Elotuzumab's Promise

The study will explore the role of elotuzumab in combination with bortezomib, lenalidomide, and dexamethasone (VRD) as induction and consolidation treatment, followed by lenalidomide maintenance. It's like adding a new, stronger camel to a caravan, providing additional strength and resources to navigate the difficult journey of treating myeloma.

A Hope for Deeper Remissions: Navigating the Desert of Myeloma

This research offers hope for patients with multiple myeloma. Elotuzumab's unique targeting mechanism and potential to improve remission rates and overall survival offer a new path through the desert of this challenging disease. It's a journey towards a brighter future, where patients have more effective and targeted treatment options.

Dr.Camel's Conclusion

This study represents a promising step forward in the fight against multiple myeloma. Elotuzumab, with its targeted approach and potential to improve treatment outcomes, offers a glimmer of hope for a future where myeloma patients can live longer and healthier lives. It's like finding a new oasis in the vast desert of cancer research, offering a source of refreshment and hope for a brighter tomorrow.

Date :
  1. Date Completed 2019-11-25
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

31138244

DOI: Digital Object Identifier

PMC6537200

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.